In vitro effects of interleukin-2 and gamma globulin on immune dysfunction in a patient with severe mucocutaneous herpes simplex virus infection.
A previously healthy woman developed severe, recurrent mucocutaneous herpes simplex virus (HSV) infection at 21 years of age. Immunologic assessment over the past 2 years has revealed persistent T-cell and natural killer cell dysfunction despite normal numbers of these cells as measured by flow cytometry. We studied the effect of recombinant interleukin 2 (rIL-2) and gamma globulin on the patient's mononuclear cells in 18-hour 51Cr release assays using HSV-infected and uninfected target cells. Both gamma globulin and rIL-2 significantly enhanced target cell lysis of HSV-infected target cells (P less than .001), but did not increase lysis of uninfected target cells. Addition of the patient's serum had no effect on HSV-infected target cell lysis despite a high HSV IgG titer, indicating a possible specific abnormality in production of antibody-dependent cellular cytotoxicity antibody.
Wise
S L
SL
Section of Allergy/Immunology, Medical College of Georgia, Augusta.
Yarbrough
J A
JA
Stafford
C T
CT
Leffell
M S
MS
Thompson
W O
WO
Ades
E W
EW
D000328:Adult; D000920:Antibody-Dependent Cell Cytotoxicity; D003602:Cytotoxicity, Immunologic; D005260:Female; D006561:Herpes Simplex / Q000276:immunology / Q000628:therapy*; D006801:Humans; D007113:Immunity, Innate; D007167:Immunotherapy; D007376:Interleukin-2 / Q000627:therapeutic use*; D007694:Killer Cells, Natural / Q000276:immunology; D016131:Lymphocyte Subsets / Q000276:immunology; D012008:Recurrence; D013601:T-Lymphocytes / Q000276:immunology; D005719:gamma-Globulins / Q000627:therapeutic use*
D007376:Interleukin-2; D005719:gamma-Globulins